Sumanta Kumar Pal, MD, FASCO - Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

English - December 14, 2023 23:00 - 58 minutes - ★★★★ - 8 ratings
Science cme medical education cme credits peerview insession inreview oncology hematology cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Bradley J. Monk, MD, FACS, FACOG - The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer

Next Episode: Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DJA865. CME/MOC/AAPA credit will be available until December 10, 2024.

Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, and Exelixis, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Allogene Therapeutics; CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.

Faculty/Planner
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Eisai Co., Ltd.; F. Hoffmann-La Roche AG; Ipsen Pharma.; Janssen Global Services, LLC.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis AG; and Pfizer all paid to institution.

Faculty/Planner
David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.